Good morning,

Today I actually bought the first tranche of the following shares:

Intel - Arm Holding - Nokia - Pfizer

---------------------------------------------------------------------------------------------

$INTC (-3,28 %) Nobody believes me, but I actually wanted to buy Intel last week before the significant rise, after the rise I speculated on a setback, which didn't turn out to be so strong and today I simply bought.

Why Intel? What distinguishes Intel from AMD and NVIDIA?

Intel is the only one that develops and also produces itself. Of course, this also entails risks, but it is also the case that Intel is the only non $MU (+3,79 %) is the only non-Asian chip manufacturer that has the latest ASML machines. Is that not one of the reasons why even Nvidia is now investing in Intel... By the way, I actually bought Micron today, simply to increase the size of the position.

In my opinion, anyone investing in Intel today should have a lot of patience. As you know, I don't have much of that, so maybe this will be my gym.

--------------------------------------------------------------------------------------------------------

$ARM (+0,17 %) Arm develops the Arm architecture for processors, which are particularly efficient and do not require cooling, which is why you find them as standard in smartphones, tablets and other devices, and sells the licenses to Qualcomm, Apple, Samsung and Nvidia, for example.

They are involved in almost all smartphone chips, earning money from the license without having to bear any production costs themselves.

The risks are a very high valuation, in which a lot of growth is already priced in. Strong dependence on the smartphone market, competitors could contest market shares and the company is very dependent on the Asian market.

--------------------------------------------------------------------------------------------------------

$NOKIA (+0,03 %) is quite well positioned and a leader in 5G network technology. For example, it controls over 29% of the 5G market outside China and is already in the lead in 6G... The business model is quite cyclical, investment intensive and the technological change is very fast.

--------------------------------------------------------------------------------------------------------

$PFE (+0,2 %) has made many strategic acquisitions in recent years. The acquisitions of Seagen and currently Metsera, among others, show that Pfizer is making targeted investments in growing and lucrative therapeutic areas. Whether the pipeline will be successful remains to be seen and is probably one of the greater risks.

--------------------------------------------------------------------------------------------------------

I have mentioned some of the risks, there are probably countless. The stocks fit into my portfolio quite well, as I mainly invest in boring ETFs and the weighting of these individual stocks is too low to significantly jeopardize my basic investment. If things go really badly, the money is gone, if things go reasonably badly, I have dividend stocks 🤪

The US pharmaceutical giant has so far had little success with the development of its own slimming product. According to a media report, it is now set to enter the market in a different way.

According to a newspaper report, the pharmaceutical group Pfizer is on the verge of acquiring the US company Metsera, which specializes in weight loss drugs. As the "Financial Times" reported, citing unnamed sources, the takeover with a volume of up to 7.3 billion dollars could be announced as early as Monday. Pfizer and Metsera were initially unavailable for comment.

According to the report, Pfizer wants to pay 47.50 dollars per Metsera share in cash. In addition, a further 22.50 dollars per share would be linked to the achievement of certain targets. The bid of 47.50 dollars per share corresponds to a premium of more than 40 percent on Metsera's closing price on Friday. At that time, the company had a market capitalization of around 3.5 billion dollars.

With the acquisition, Pfizer wants to secure a place in the lucrative market for weight loss drugs. The company had suffered setbacks in the development of its own drugs. Work on an experimental weight loss pill called Danuglipron was abandoned in April after a mid-stage study showed poor tolerability. A single daily dose version that was later tested on 1,400 patients raised concerns about effects on the liver.

Metsera was founded in 2022 and celebrated a brilliant debut on the US technology exchange Nasdaq in January. The company's most advanced drug candidate in development, MET-097i, showed an average weight loss of 11.3 percent in a mid-stage trial, according to the company.

The demand for weight loss drugs is growing rapidly, with competitors Eli Lilly and Novo Nordisk battling for market leadership. Some experts predict that the global market for weight loss drugs could reach a value of 150 billion dollars by the early 2030s.

$MTSR
$PFE (+0,2 %)

https://www.spiegel.de/wirtschaft/milliardeninvesittion-pfizer-vor-uebernahme-von-abnehm-spezialist-metsera-a-fb607b84-e636-480f-a238-5b30c813c7bd

A sector that has lost so much ground in recent years, I think it's time to put something in the portfolio, I was undecided between $MRK (-0,15 %) e $PFE (+0,2 %) but seeing the data the former has had a steady growth in earnings, revenues and R&D investment, as well as a lower payout ratio than Pfizer and a higher dividend increase over time, more than sustainable by the way, another interesting factor is the exchange rate, a purchase gone through at the exchange rate of 1.1737, much better than the previous purchase of $MAIN (-0,35 %) which took place for 1.1699 eur/usd.

I would have loved to have added$O (+0,17 %) to ride the wave of the rate cut but the broker Directa only reserves it for "professional" clients, a scam....

As things stand right now I would say that for the next month I am going to add an ETF between $ISPA (-0,14 %) e $VHYL (-0,17 %) , I intend to have both in the future but following a contrarian strategy, that is, buying the one that has lost the most in the past month (or gained the least).

Today $PFE (+0,2 %) for $ROG (+0,68 %) exchanged. On the one hand, I see Roche as a country diversification. I accept the lower dividend and hope for more growth.

$

$NOVO B (-0,59 %)
$NVO (-0,47 %)
$UNH (+0,09 %)
$MRK (-0,15 %)
$JNJ (+0,82 %)
$XDWH (+0,08 %)
$PFE (+0,2 %)
$LLY (-0,03 %)

I am curious to see how the European stock markets will react today, but with the RSI extremely oversold and I could well imagine a bounce at 300 Danish kroner.

Is anyone here trying their luck as a trader and is so tired of life with leverage? 😂

@Multibagger put another one on top ? Do you have a good certificate for that ?

The 17 largest pharmaceutical companies were written to and given a deadline of September 29 to lower their prices, otherwise Trump himself will come by. 😈

The S&P500 pharma sector was the weakest sector today with -2.2 %.

$AZN (+0,12 %)

$BMY (+0,19 %)

$LLY (-0,03 %)

$PFE (+0,2 %)

$ABT (-0,82 %)

$JNJ (+0,82 %)

$NOVO B (-0,59 %)

$UNH (+0,09 %)

$MRK (-0,15 %)

$SAN (-0,02 %)

$WHCS (+0,29 %)

https://www.statnews.com/2025/07/31/trump-most-favored-nations-drug-pricing-lower-pharmaceutical-prices/